Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates.
Drug delivery
Paclitaxel
Prostate cancer
Prostate-specific membrane antigen
Journal
Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377
Informations de publication
Date de publication:
15 08 2019
15 08 2019
Historique:
received:
08
05
2019
revised:
17
06
2019
accepted:
19
06
2019
pubmed:
30
6
2019
medline:
18
9
2020
entrez:
29
6
2019
Statut:
ppublish
Résumé
Prostate cancer (PC) is the second most commonly occurring cancer in men. Conventional chemotherapy has wide variety of disadvantages such as high systemic toxicity and low selectivity. Targeted drug delivery is a promising approach to decrease side effects of therapy. Prostate specific membrane antigen (PSMA) is overexpressed in prostate cancer cells while low level of expression is observed in normal cells. In this study we describe the development of Glu-urea-Lys based PSMA-targeting conjugates with paclitaxel. A series of new PSMA targeting conjugates with paclitaxel was designed and synthesized. The cytotoxicity of conjugates was evaluated against prostate (LNCaP, 22Rv1 and PC-3) and non-prostate (Hek293T, VA13, A549 and MCF-7) cell lines. The most promising conjugate 21 was examined in vivo using 22Rv1 xenograft mice model. It demonstrated good efficiency comparable with paclitaxel, while reduced toxicity. 3D molecular docking study was also performed to understand underlying mechanism of binding and further optimization of the linker substructure and conjugates structure for improving the target affinity. These conjugates may be useful for further design of novel PSMA targeting delivery systems for PC.
Identifiants
pubmed: 31248772
pii: S0960-894X(19)30412-3
doi: 10.1016/j.bmcl.2019.06.035
pii:
doi:
Substances chimiques
Paclitaxel
P88XT4IS4D
Types de publication
Letter
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2229-2235Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.